Core Insights - Agios Pharmaceuticals reported strong execution in 2025, highlighted by the U.S. approval and launch of AQVESME, the first treatment for anemia in adults with thalassemia, which has received positive feedback from the community [2][5] - The company aims to expand its product portfolio and pipeline, focusing on high-value indications such as sickle cell disease and myelodysplastic syndromes, while maintaining disciplined capital allocation [2] Financial Performance - For Q4 2025, Agios reported net revenues of $20.0 million from PYRUKYND, with a full-year total of $54.0 million, marking a 49% increase from Q4 2024 [5][12] - The net loss for Q4 2025 was $108.0 million, compared to a net loss of $96.5 million in Q4 2024 [8] - Total revenues for the year 2025 reached $54.0 million, up from $36.5 million in 2024 [15] Research and Development Highlights - AQVESME received FDA approval in December 2025 and is now available in the U.S. [6][12] - A pre-sNDA meeting with the FDA for mitapivat in sickle cell disease is scheduled for Q1 2026, with plans to submit a marketing application thereafter [5][6] - The Phase 2 trial of tebapivat in sickle cell disease has been fully enrolled, with topline results expected in the second half of 2026 [7] Cash Position - As of December 31, 2025, Agios had $1.2 billion in cash, cash equivalents, and marketable securities, down from $1.5 billion a year earlier [12][14] - The company anticipates that its financial resources will support the U.S. launch of AQVESME and the advancement of its clinical programs [12]

Core Insights - Agios Pharmaceuticals has outlined its strategic priorities and key milestones for 2026, focusing on the launch of AQVESME™ and expansion into additional indications for its PK activation franchise [1][3] Company Performance - In 2025, Agios achieved significant progress, highlighted by the U.S. approval of AQVESME™, the first medicine approved for treating anemia in adults with alpha- or beta-thalassemia [2][9] - The company aims to become a sustainable and diversified rare disease company, leveraging its existing commercial presence [2][3] 2026 Strategic Priorities - The company plans a high-impact U.S. launch of AQVESME in thalassemia and seeks to expand its PK activation franchise into sickle cell disease and lower-risk myelodysplastic syndromes [3][8] - Agios is committed to disciplined capital allocation and operational efficiency to support long-term sustainability [3] Anticipated Milestones - AQVESME's U.S. commercial launch is set for late January 2026, following FDA approval in December 2025 [9] - A pre-sNDA meeting with the FDA for mitapivat in sickle cell disease is anticipated in Q1 2026, with a regulatory submission to follow [8][9] - Topline results from the Phase 2b trial of tebapivat in lower-risk myelodysplastic syndromes are expected in the first half of 2026 [6][8] - Enrollment in the Phase 2 sickle cell disease trial of tebapivat was initiated in 2025, with topline results expected in the second half of 2026 [9] Pipeline Development - Agios is advancing its early- and mid-stage pipeline across multiple high-value indications, including a Phase 1 trial of AG-236 for polycythemia vera and a Phase 1b trial of AG-181 for phenylketonuria [10][11]

Group 1 - UiPath Inc. will join the S&P Midcap 400, replacing Synovus Financial Corp., effective January 2, 2026, leading to a 6.8% increase in shares to $17.05 in after-hours trading [1] - Agios Pharmaceuticals Inc. received FDA approval for AQVESME™ for treating anemia in adults with alpha- or beta-thalassemia, but shares fell 1.4% to $24.59 [1] - Can Fite Biopharma announced a 1-for-3,000 reverse share split, resulting in a 28.8% drop in shares to $0.17 in after-hours trading [1] - Citius Pharmaceuticals reported a quarterly loss of 11 cents per share, better than the expected loss of 43 cents, causing shares to surge 22.1% to $1.27 [1] - Ramaco Resources announced a $100 million stock repurchase plan, leading to a 7.1% increase in shares to $18.09 in after-hours trading [1]

Core Insights - Agios Pharmaceuticals has received FDA approval for AQVESME™ (mitapivat), the first oral pyruvate kinase activator for treating anemia in adults with alpha- or beta-thalassemia, making it the only FDA-approved treatment for both non-transfusion-dependent and transfusion-dependent forms of the disease [1][3][4] Group 1: FDA Approval and Clinical Trials - The FDA approval is based on the results from the ENERGIZE and ENERGIZE-T Phase 3 trials, which included 452 patients and demonstrated significant improvements in hemolytic anemia, hemoglobin levels, and fatigue compared to placebo [2][9][10] - The ENERGIZE trial involved 194 non-transfusion-dependent patients, while the ENERGIZE-T trial included 258 transfusion-dependent patients, both showing positive efficacy endpoints [10][11] Group 2: Impact on Thalassemia Community - The approval of AQVESME is seen as a landmark moment for the thalassemia community, providing a new treatment option for approximately 6,000 adult patients in the U.S. who suffer from this debilitating disease [2][8] - The introduction of AQVESME is expected to address the urgent needs of patients, particularly in reducing the need for regular blood transfusions and improving quality of life [3][4] Group 3: Safety and Risk Management - Due to the risk of hepatocellular injury, AQVESME will be available only through a Risk Evaluation and Mitigation Strategy (REMS) program, which includes regular liver function tests and education for patients and healthcare providers [14][15][18] - In clinical trials, 5 patients experienced adverse reactions suggestive of hepatocellular injury, with 2 requiring hospitalization, highlighting the importance of monitoring liver health during treatment [17][19] Group 4: Market Availability - AQVESME is expected to be available in the U.S. by late January 2026, following the implementation of the REMS program [4][5] - The drug will be marketed under the AQVESME brand name for thalassemia, while continuing to be marketed as PYRUKYND® for PK deficiency, which does not require a REMS program [4][5]